Drug Trial Radar · NCT04470167
Phase 1/2 Clinical Study of TPX-115 in Patients With Partial-Thickness Rotator Cuff Tear
Last checked: Nov 20, 2026Latest source record: May 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
49
Actual
Start
Oct 26, 2020
Primary completion
Feb 17, 2022
Study completion Feb 17, 2022
Sponsor
- Lead sponsor
- Tego Science, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 14, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Rotator cuff tear is one of the most common shoulder diseases and conservative treatment is commonly used for tears involving ≤50% of tendon thickness. Since conventional conservative treatments are not fundamental to repair tendon tissue, there is a growing need of new therapy to improve structural outcome. This study assesses the safety and efficacy of allogeneic fibroblasts on partial-thickness rotator cuff tear. The primary outcome is change in American Shoulder and Elbow Surgeons (ASES) score at 24 weeks after TPX-115 injection. Secondary outcomes include changes from baseline in Visual Analogue Score (VAS) pain score, functional evaluations including Range of Motion (ROM), Constant Score (CS), ASES score and Simple Shoulder Test (SST) at 4, 12 and 24 weeks after administration and structural evaluation using MRI at 24 weeks after injection.
Conditions
- Rotator Cuff Injuries
Interventions
TPX-115Biological
Ultrasound-guided intratendinous injection of allogeneic fibroblasts(TPX-115)
PlaceboOther
Ultrasound-guided intratendinous placebo injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in shoulder score of American Shoulder and Elbow Surgeons (ASES)Time frame: 24 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Seoul National University Hospital
Seoul, South Korea
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.